Eisai Co. Ltd., of Tokyo, said a new subgroup analysis showed significant improvement in progression-free survival with lenvatinib in radioiodine-refractory differentiated thyroid cancer compared with placebo, 18.3 months vs. 3.6 months. Results are being presented at the European Thyroid Association 38th Annual Meeting.